Recently, a study on RIT for synovial sarcoma with a therapeutic agent that conjugates α-emitter actinium (225Ac) to an FZD10 antibody was reported, achieving a 60 % complete remission against a mouse model (Sudo et al., 2022). The gene discussed is FZD10; the disease is synovial sarcoma.